NRSN vs. BLRX, AFMD, CALC, THTX, LPTX, MURA, AEON, RPHM, IMMX, and CARM
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include BioLineRx (BLRX), Affimed (AFMD), CalciMedica (CALC), Theratechnologies (THTX), Leap Therapeutics (LPTX), Mural Oncology (MURA), AEON Biopharma (AEON), Reneo Pharmaceuticals (RPHM), Immix Biopharma (IMMX), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, BioLineRx had 13 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 16 mentions for BioLineRx and 3 mentions for NeuroSense Therapeutics. BioLineRx's average media sentiment score of 0.85 beat NeuroSense Therapeutics' score of 0.68 indicating that BioLineRx is being referred to more favorably in the news media.
1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
NeuroSense Therapeutics has higher earnings, but lower revenue than BioLineRx. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
BioLineRx's return on equity of -325.10% beat NeuroSense Therapeutics' return on equity.
NeuroSense Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
BioLineRx has a consensus price target of $21.00, indicating a potential upside of 2,716.52%. Given BioLineRx's higher probable upside, analysts plainly believe BioLineRx is more favorable than NeuroSense Therapeutics.
BioLineRx received 502 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 73.36% of users gave BioLineRx an outperform vote.
Summary
BioLineRx beats NeuroSense Therapeutics on 10 of the 14 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
